



CHINA TIANJIN

Strengthening **TIDES Capabilities** to Meet Rising Development and Manufacturing Demand

As global demand for TIDES therapeutics accelerates, Asymchem is expanding manufacturing and R&D capabilities to accelerate programs from preclinical to commercial success.



Expanding TIDES Manufacturing

Peptide Plant 4 installation is underway at Tianjin 4 site, scheduled for commissioning by **October 2026**. Featuring multiple new 100L–3000L reactors, it will significantly expand peptide manufacturing capacity.

Two additional OligoProcess™ units are on track for operation by **March 2026**, further reinforcing Asymchem's integrated TIDES capabilities.

Advancing TIDES R&D

A **second TIDES-dedicated R&D center** is progressing in parallel and is expected to become operational by the **end of December 2026**, enhancing analytical and quality control capabilities that support TIDES manufacturing.



With seamless transition from development to commercial manufacturing, Asymchem continues delivering **fully integrated solutions** for partners worldwide.

New Accreditations Reinforce Commitment to Sustainability Excellence

Asymchem is pleased to announce two significant achievements at our Sandwich site, reinforcing our commitment to excellence and our position as a trusted pharmaceutical partner.

PSCI Audit Success

The recent PSCI audit confirmed our strong performance across **health & safety**, **environmental management**, and **governance**, validating that our systems are robust and our standards align with global best practice.

ISO 14001 Certification



Achieving ISO 14001 certification recognizes our **effective environmental management system** and commitment to **reducing environmental impact**, marking a significant milestone in our sustainability journey.

Asymchem remain focused on continuous improvement and delivering the performance our clients trust. Thank you for your continued partnership and confidence in us.

Learn more about our Sandwich site at:

www.asymchem.co.uk

